Protavio is pleased to announce our participation in the 8th Network Meeting for Users of Multiplex Immune Assays held in Copenhagen, Denmark. Our co-founder, Dr. Leonidas Alexopoulos, delivered a presentation on how Protavio has successfully implemented a GMP production process and ISO13485 quality management system to manufacture Luminex serological assays.
Dr. Alexopoulos highlighted the GMP production of multiplex serological assays utilizing the Luminex xMAP platform. This technology enables the simultaneous assessment of multiple biomarkers, offering a comprehensive evaluation of immune responses following vaccination. The focus on immunogenicity assessment is particularly crucial for clinical trials, where understanding the immune response is essential for vaccine development and approval.
During the presentation, Dr. Alexopoulos shared insightful examples involving pneumococcal vaccines and the use of our GMP assays for the production of other pediatric vaccines. These case studies demonstrated how Protavio’s Luminex serological assays can be employed to monitor vaccine efficacy and safety, ultimately contributing to better healthcare outcomes for children worldwide.